Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gary Schuster

Internal Medicine Bellevue, WA Medical Doctor

NPI 1053500223 CMS profile 274504

1600 116Th Ave Ne, Ste 202, Bellevue, WA 98004

Open in the dashboard

General payments

$15,533

799 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gary Schuster of Bellevue, WA is reported in the CMS Open Payments database as having received $15,533 across 799 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,096 90
2024 General $2,497 110
2023 General $2,185 100
2022 General $2,144 123
2021 General $2,776 171
2020 General $1,577 77
2019 General $2,257 128

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gary Schuster
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Gary Schuster were reported at $2,096. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Gary Schuster Internal Medicine median Middle half National median
2019 $2,257 $159 $48–$570 $163
2020 $1,577 $119 $33–$402 $114
2021 $2,776 $135 $37–$521 $132
2022 $2,144 $141 $42–$496 $149
2023 $2,185 $149 $45–$519 $160
2024 $2,497 $154 $47–$537 $164
2025 $2,096 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,682 83 payments
  2. Amgen Inc. $1,549 77 payments
  3. Pfizer Inc. $1,433 66 payments
  4. AstraZeneca Pharmaceuticals LP $1,229 60 payments
  5. Biohaven Pharmaceuticals, Inc. $581 56 payments
  6. Novo Nordisk Inc $572 32 payments
  7. Teva Pharmaceuticals USA, Inc. $557 27 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $545 26 payments
  9. Lilly USA, LLC $518 27 payments
  10. Biohaven Pharmaceutical Holding Company Ltd. $514 39 payments
  11. Other $6,354 306 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $15,232 793 payments
  2. Education $302 6 payments
Products named General payments · program years 2019–2025
  1. NURTEC ODT Primary Care $1,095 95 payments
  2. Repatha $901 51 payments
  3. NURTEC ODT Pain $891 38 payments
  4. UBRELVY $831 42 payments
  5. AIMOVIG $692 40 payments
  6. XIFAXAN $545 26 payments
  7. LINZESS $452 22 payments
  8. BREZTRI $418 20 payments
  9. Ozempic $407 23 payments
  10. QULIPTA $390 17 payments
  11. Other $12,794 635 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$137,817

Of which drugs: $5,913

Medicare patients

237

Average age 74

Services billed

3,321

107 women, 130 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 62%
Arthritis 62%
Ischemic heart disease 38%
Diabetes 19%
Cancer 18%
Atrial fibrillation 13%
Osteoporosis 13%
Heart failure 10%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 36 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NURTEC ODT
$378 — —
XIFAXAN
$192 — —
VOQUEZNA
$123 — —
AIRSUPRA
$123 — —
QUVIVIQ
$121 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 36 with Patron

Records

799 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record